HLA-DPB1 molecular mismatches are risk factors for acute rejection and low 5-year graft function in first kidney transplants
Renato de Marco
Instituto de Imunogenética (IGEN), Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil
Search for more papers by this authorLúcio R. Requião-Moura
Nephrology Division, Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil
Search for more papers by this authorTamiris R. F. Raimundo
Instituto de Imunogenética (IGEN), Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil
Search for more papers by this authorTuíla B. Mourão
Instituto de Imunogenética (IGEN), Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil
Search for more papers by this authorGisele F. Rampim
Instituto de Imunogenética (IGEN), Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil
Search for more papers by this authorJosé O. Medina-Pestana
Nephrology Division, Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil
Search for more papers by this authorHélio Tedesco-Silva
Nephrology Division, Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil
Search for more papers by this authorCorresponding Author
Maria Gerbase-DeLima
Instituto de Imunogenética (IGEN), Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil
Correspondence
Maria Gerbase-DeLima, Rua Loefgren 1235, 04040-031 São Paulo, SP, Brazil.
Email: [email protected]
Search for more papers by this authorRenato de Marco
Instituto de Imunogenética (IGEN), Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil
Search for more papers by this authorLúcio R. Requião-Moura
Nephrology Division, Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil
Search for more papers by this authorTamiris R. F. Raimundo
Instituto de Imunogenética (IGEN), Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil
Search for more papers by this authorTuíla B. Mourão
Instituto de Imunogenética (IGEN), Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil
Search for more papers by this authorGisele F. Rampim
Instituto de Imunogenética (IGEN), Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil
Search for more papers by this authorJosé O. Medina-Pestana
Nephrology Division, Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil
Search for more papers by this authorHélio Tedesco-Silva
Nephrology Division, Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil
Search for more papers by this authorCorresponding Author
Maria Gerbase-DeLima
Instituto de Imunogenética (IGEN), Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil
Correspondence
Maria Gerbase-DeLima, Rua Loefgren 1235, 04040-031 São Paulo, SP, Brazil.
Email: [email protected]
Search for more papers by this authorFunding information: Associação Fundo de Incentivo à Pesquisa
Abstract
The study aimed to investigate the impact of HLA-DPB1 allelic and molecular mismatches on the occurrence of acute rejection (AR) and low 5-year graft function (5Y-GF) in first kidney transplant (KT) recipients. This is a single center retrospective study of 130 deceased donor KT recipients transplanted between 2014 and 2016. HLA-DPB1 allelic MM and the following molecular MM (mMM) were analyzed: expression MM with the high expression G allele in the donor; T cell epitope MM (TCE MM); epitope MM (EMM), considering all six hypervariable regions (EMM-ABCDEF HVR), or only ABEF regions (EMM-ABEF HVR); eplet MM (EpMM); antibody-verified eplet MM (AbVer EpMM); and solvent accessible amino acid MM (SAMM). There was no association of allelic MM with AR or 5Y-GF. The variables independently associated (Cox regression analyses) with AR were high donor final creatinine, nonpermissive TCE MM, ABCDEF EMM load ≥6, EpMM load ≥6; SAMM load ≥5, and AbVer EpMM load ≥3. No association between any HLA-DPB1 mMM and 5Y-GF was observed when all 130 transplant recipients were considered. However, when transplants from expanded criteria donors were excluded, independent associations were detected (logistic regression analyses) with AbVerEpMM load ≥2, SAMM load ≥7, cerebro-vascular death, donor age, and AR. To our knowledge, this is the first study that shows that some HLA-DPB1 mMM are associated with AR and low 5Y-GF in a population of exclusively first kidney transplant recipients.
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
Filename | Description |
---|---|
tan14911-sup-0001-Tables.docxWord 2007 document , 25.4 KB | Supplementary Table 1. Multivariate logistic regression for 5-year graft function in the entire cohort (n = 130) considering clinical variables which reached a p-value <0.05 in the univariate analyses and ABEF EMM load. Supplementary Table 2. Multivariate logistic regression for 5-year graft function in the entire cohort (n = 130) considering baseline variables which reached a p-value <0.05 in the univariate analyses, acute rejection and HLA-DPB1 SAMM load. Supplementary Table 3. Baseline characteristics of 93 first kidney transplants from standard criteria donors, stratified by low (eGFR ≤40 ml/min/1.73 m2) or high (eGFR >40 ml/min/1.73 m2) 5-year graft function (5Y-GF). Univariate analyses. Supplementary Table 4. Multivariate logistic regression including baseline characteristics and HLA-DPB1 A, B, E, and F hypervariable regions mismatches (ABEF EMM ≥ 7), for low 5-year graft function in 93 primary kidney transplants from standard criteria donors. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Mytilineos J, Deufel A, Opelz G. Clinical relevance of HLADPB locus matching for cadaver kidney retransplants: a report of the collaborative transplant study. Transplantation. 1997; 63: 1351-1354.
- 2Tang C, Unterrainer C, Fink A, et al. Analysis of de novo donor-specific HLA-DPB1 antibodies in kidney transplantation. HLA. 2021; 98: 423-430.
- 3Duquesnoy RJ, Awadalla Y, Lomago J, et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR, DQ. DP Epitopes Transpl Immunol. 2008; 18: 352-360.
- 4Thaunat O, Hanf W, Dubois V, et al. Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. Transpl Immunol. 2009; 20: 209-211.
- 5Billen EV, Christiaans MH, Doxiadis II, Voorter CE, van den Berg-Loonen EM. HLA-DP antibodies before and after renal transplantation. Tissue Antigens. 2010; 75: 278-285.
- 6Singh P, Colombe BW, Francos GC, Martinez Cantarin MP, Frank AM. Acute humoral rejection in a zero mismatch deceased donor renal transplant due to an antibody to an HLA-DP alpha. Transplantation. 2010; 90: 220-221.
- 7Gilbert M, Paul S, Perrat G, et al. Impact of pretransplant human leukocyte antigen-C and -DP antibodies on kidney graft outcome. Transplant Proc. 2011; 43: 3412-3414.
- 8Jolly EC, Key T, Rasheed H, et al. Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation. Am J Transplant. 2012; 12: 2845-2848.
- 9Mierzejewska B, Schroder PM, Baum CE, et al. Early acute antibody-mediated rejection of a negative flow crossmatch 3rd kidney transplant with exclusive disparity at HLA-DP. Hum Immunol. 2014; 75: 703-708.
- 10Cippà PE, Gaspert A, Etter C, et al. Late antibody-mediated rejection by de novo donor HLA-DP-specific antibody after renal transplantation: a case report. Hum Immunol. 2014; 75: 462-465.
- 11Hörmann M, Dieplinger G, Rebellato LM, et al. Incidence and impact of anti-HLA-DP antibodies in renal transplantation. Clin Transplant. 2016; 30: 1108-1114.
- 12Bachelet T, Martinez C, del Bello A, et al. Deleterious impact of donor-specific anti-HLA antibodies toward HLA-Cw and HLA-DP in kidney transplantation. Transplantation. 2016; 100: 59-66.
- 13Nikaein A, Lerman M, Rofaiel G, Allam SR. Single center observation of the role of pre-existing HLA-DP antibodies in humoral rejection following renal transplantation. Transpl Immunol. 2018; 51: 58-61.
- 14Thammanichanond D, Parapiboon W, Mongkolsuk T, Worawichawong S, Tammakorn C, Kitpoka P. Acute antibody-mediated rejection by de novo anti-HLA-DPβ and -DPα antibodies after kidney transplantation: a case report. Transplant Proc. 2018; 50: 2548-2552.
- 15Daniëls L, Claas FHJ, Kramer CSM, et al. The role of HLA-DP mismatches and donor specific HLA-DP antibodies in kidney transplantation: a case series. Transpl Immunol. 2020; 65:101287.
- 16Petersdorf EW, Gooley T, Malkki M, et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol. 2001; 112: 988-994.
- 17Shaw BE, Potter MN, Mayor NP, et al. The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation. Bone Marrow Transplant. 2003; 31: 1001-1008.
- 18Fleischhauer K, Shaw BE, Gooley T, et al. International histocompatibility working Group in Hematopoietic Cell Transplantation. Effect of T-cell epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012; 13: 66-74.
- 19Fleischhauer K, Fernandez-Viña MA, Wang T, et al. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. Bone Marrow Transplant. 2014; 49: 1176-1183.
- 20Crivello P, Zito L, Sizzano F, et al. The impact of amino acid variability on alloreactivity defines a functional distance predictive of permissive HLA-DPB1 mismatches in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015; 21: 233-241.
- 21Petersdorf EW, Malkki M, O'huigin C, et al. High HLA-DP expression and graft-versus-host disease. N Engl J Med. 2015; 373: 599-609.
- 22Petersdorf EW, Bengtsson M, De Santis D, et al. Role of HLA-DP expression in graft-versus-host disease after unrelated donor transplantation. J Clin Oncol. 2020; 38: 2712-2718.
- 23Laux G, Mansmann U, Deufel A, Opelz G, Mytilineos J. A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation. 2003; 75: 1527-1532.
- 24Bugawan TL, Begovich AB, Erlich HA. Rapid HLA-DPB typing using enzymatically amplified DNA and nonradioactive sequence-specific oligonucleotide probes. Immunogenetics. 1990; 32: 231-241.
- 25Duquesnoy RJ, Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol. 2007; 68: 12-25.
- 26El-Awar N, Jucaud V, Nguyen A. HLA epitopes: the targets of monoclonal and alloantibodies defined. J Immunol Res. 2017; 2017: 3406230.
- 27Sapir-Pichhadze R, Tinckam K, Quach K, et al. HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested case-control study. Am J Transplant. 2015; 15: 137-148.
- 28Lachmann N, Niemann M, Reinke P, et al. Donor-recipient matching based on predicted indirectly recognizable HLA epitopes independently predicts the incidence of de novo donor-specific HLA antibodies following renal transplantation. Am J Transplant. 2017; 17: 3076-3086.
- 29Wiebe C, Kosmoliaptsis V, Pochinco D, Taylor CJ, Nickerson P. A comparison of HLA molecular mismatch methods to determine HLA immunogenicity. Transplantation. 2018; 102: 1338-1343.
- 30Kumru Sahin G, Unterrainer C, Süsal C. Critical evaluation of a possible role of HLA epitope matching in kidney transplantation. Transplant Rev. 2020; 34:100533.
- 31Wiebe C, Kosmoliaptsis V, Pochinco D, et al. HLA-DR/DQ molecular mismatch: a prognostic biomarker for primary alloimmunity. Am J Transplant. 2019; 19: 1708-1719.
- 32Mohammadhassanzadeh H, Oualkacha K, Zhang W, et al. On path to informing hierarchy of Eplet mismatches as determinants of kidney transplant loss. Kidney Int Rep. 2021; 6: 1567-1579.
- 33Kramer CSM, Koster J, Haasnoot GW, Roelen DL, Claas FHJ, Heidt S. HLA-EMMA: a user-friendly tool to analyse HLA class I and class II compatibility on the amino acid level. HLA. 2020; 96: 43-51.
- 34Mine KL, Tedesco-Silva H, Mourão TB, et al. Heightened expression of HLA-DQB1 and HLA-DQB2 in pre-implantation biopsies predicts poor late kidney graft function. Hum Immunol. 2018; 79: 594-601.
- 35Mine KL, de Marco R, Raimundo TRF, et al. High soluble HLA-DQB2 levels in posttransplant serum are associated with kidney graft dysfunction. Int J Immunogenet. 2022; 49: 63-69.
- 36Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008; 8: 753-760.
- 37Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53: 766-772.
- 38Hurley CK, Kempenich J, Wadsworth K, et al. Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0. HLA. 2020; 95: 516-531.
- 39Schöne B, Bergmann S, Lang K, et al. Predicting an HLA-DPB1 expression marker based on standard DPB1 genotyping: linkage analysis of over 32,000 samples. Hum Immunol. 2018; 79: 20-27.
- 40Shieh M, Hayeck TJ, Dinh A, et al. Complex linkage disequilibrium effects in HLA-DPB1 expression and molecular mismatch analyses of transplantation outcomes. Transplantation. 2021; 105: 637-647.
- 41Sanchez-Mazas A, Djoulah S, Busson M, et al. A linkage disequilibrium map of the MHC region based on the analysis of 14 loci haplotypes in 50 French families. Eur J Hum Genet. 2000; 8: 33-41.
- 42Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. Am J Transplant. 2003; 3(Suppl 4): 114-125.
- 43Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. Jama. 2005; 294: 2726-2733.
- 44Rao PS, Ojo A. The alphabet soup of kidney transplantation: SCD, DCD, ECD-fundamentals for the practicing nephrologist. Clin J Am Soc Nephrol. 2009; 4: 1827-1831.
- 45Shaw BE, Mayor NP, Russell NH, et al. Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia. 2010; 24: 58-65.
- 46Unterrainer C, Döhler B, Niemann M, Lachmann N, Süsal C. Can PIRCHE-II matching outmatch traditional HLA matching? Front Immunol. 2021; 12:631246.